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Abstract
Background: NF-κB is implicated in gene regulation involved in neuronal survival, inflammmatory
response and cancer. There are relatively few neuronal target genes of NF-κB characterized.
Results: We have identified the neuronal cyclooxygenase-2 (COX-2) as a NF-κB target gene. In
organotypic hippocampal slice cultures constitutive NF-κB activity was detected, which was
correlated with high anti-COX-2 immunoreactivity. Aspirin a frequently used painkiller inhibits
neuronal NF-κB activity in organotypic cultures resulting in a strong inhibition of the NF-κB target
gene COX-2. Based on these findings, the transcriptional regulation of COX-2 by NF-κB was
investigated. Transient transfections showed a significant increase of COX-2 promoter activity
upon stimulation with PMA, an effect which could be obtained also by cotransfection of the NF-κB
subunits p65 and p50. In the murine neuroblastoma cell line NB-4, which is characterized by
constitutive NF-κB activity, COX-2 promoter activity could not be further increased with PMA or
TNF. Constitutive promoter activity could be repressed upon cotransfection of the inhibitory
subunit IκB-α. EMSA and mutational analysis conferred the regulatory NF-κB activity to the
promoter distal κB-site in the human COX-2 promoter.
Conclusions: NF-κB regulates neuronal COX-2 gene expression, and acts as an upstream target
of Aspirin. This extends Aspirin's mode of action from a covalent modification of COX-2 to the
upstream regulation of COX-2 gene expression in neurons.
Background
NF-κB a transcription factor with inducible activity,
present in most cell types. This factor is crucially involved
in regulation of genes relevant in neuronal survival, in-
flammmatory response, cancer and innate immunity
[1,2]. The activation of NF-κB is mainly controlled at the
posttranscriptional level by complex formation with the
inhibitory subunit IκB in the cytoplasm [3]. Phosphoryla-
tion of IκB prior to degradation is catalyzed by the activa-
tion of a complex consisting of two kinases (IKK-α and
IKK-β) [4] together with a modifying subunit called
NEMO [5] or IKK-γ [6]. Binding of NEMO is important to
mediate the cytokine response in a aktivation of the kinas-
es [7]. Recently it was shown that mutations of NEMO/
IKK-γ were linked to human genetic diseases (for review
see [8]).
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NF-κB is also frequently found in different cells of the
nervous system (for review see [9]. Many neurons of the
central nervous system contain NF-κB as a heterodimer of
the DNA-binding subunits p50 and p65, complexed with
IκB [10]. Constitutive activity of NF-κB is present in fields
of the hippocampus and in the cerebral cortex [10]. These
data suggest an endogenous, physiological stimulus,
which controls the activity of NF-κB. One candidate is the
neurotransmitter glutamate, which can activate NF-κB in
cerebellar granule cells and hippocampal neurons [11–
15]. Furthermore the presence of inducible NF-κB in syn-
aptosomes [16,17] and the transport of GFP-tagged p65
from neurites to the nucleus [15] suggest that NF-κB could
be involved in connecting synaptic activity with gene ex-
pression. This notion is also supported by the ultrastruc-
tural localization of activated NF-κB in dendrites [18]. A
gene induced by synaptic activity is the inducible cycloox-
ygenase or prostaglandin H (PGH) synthase-2 (COX-2).
In contrast to peripheral tissues the cyclooxygenase-2 ac-
tivity and expression is high in normal brain, where it is
restricted to neurons [19,20]. We investigated wether
COX-2 is regulated by NF-κB. COX-2 and activated NF-κB
immunoreactivity colocalized in hippocampal and corti-
cal neurons. Aspirin, a described inhibitor of NF-κB [21]
inhibited neuronal NF-κB, leading to a robust inhibition
of COX-2 protein expression. These data were further cor-
roborated by an analysis of the COX-2 promoter. A pro-
moter distal κB element was identified as the only
functional κB-site in NB-4 neuroblastoma cells. In addi-
tion this element is also responsible for the constitutive
promoter activity. Thus the previously described constitu-
tive COX-2 activity in neurons [22] is dependent on con-
stitutive NF-κB activity.
Results
NF-κB and cyclooxygenase-2 colocalize in subsets of corti-
cal and hippocampal neurons
COX-2 was identified as a gene induced after seizures
[23]. Basal expression of this enzyme is high in brain, in
comparison to other organs were COX-1 is the major
isoenzyme. COX-2 expression in brain is dependent on
normal neuronal activity, as demonstrated with intra-oc-
ular tetrodotoxin injection which blocks COX-2 expres-
sion in the visual cortex. Moreover COX-2 expression in
the CNS is obligate neuronal [20]. Here we tested if COX-
2, as a marker of neuronal activity, is present in the same
neurons, that show activated NF-κB. Double labeling im-
munofluorescence was used to correlate the activation of
NF-κB with COX-2 protein amount at single cell level.
Previously we developed a monoclonal antibody specific
for the activated form of p65 [24]. This antibody is direct-
ed against an epitope of the nuclear localization signal
(NLS) of p65. In the non-activated cytoplasmic form of
NF-κB the NLS is predominantly covered by the inhibito-
ry subunit IκB, making binding of the antibody impossi-
ble. Upon stimulation active NF-κB is generated after IκB
degradation. This active NF-κB can be visualized with the
activity specific antibody.
Using this antibody binding predominantly to the activat-
ed form of p65 and a polyclonal antibody to COX-2, a dis-
tinct staining pattern for both proteins in rat cortex (Fig.
1) and hippocampus (Fig. 2a,2b,2c dentate gyrus; d-f
CA3) was detected. Immediately evident is the overlap of
both stainings in many, but not all neurons (arrow heads
in Fig. 1 and Fig. 2), where the activated p65 subunit is lo-
calized in the nucleus and the COX-2 protein in the corre-
sponding cytoplasm of the same neuron. In accordance
with previous findings [20,25] we detect also a perinucle-
ar localization of COX-2.
In addition to the abundant colocalization of both stain-
ings, cells with distinct staining for both COX-2 and p65
could be detected in the cortex and hippocampus. The
specificity of both antibodies was analyzed by incubation
without primary antibody, which showed no significant
staining (data not shown).
Inhibition of NF-κB leads to down regulation of COX-2 ex-
pression
To examine a causal link between nuclear NF-κB and
COX-2 expression, we investigated in hippocampal slice
cultures a possible correlation between NF-κB activation
and COX-2 expression. All cultures are treated with bicuc-
ulline and picrotoxine to interfere with GABA-ergic input.
Under these conditions NF-κB activity and COX-2 expres-
sion is similar to the in vivo situation (compare to Fig. 2).
A high level of activated NF-κB was observed in hippoc-
ampal principal cells (Fig. 3, Con). However, a co-treat-
ment with the anti-inflammatory pain killer aspirin
resulted in a robust inhibition of both, activated NF-κB
and COX-2 (Fig. 3 +aspirin). The results of a previous
study has shown that NF-κB is inhibited by aspirin [21]
via specific inhibition of the IκB kinase IKKβ [26].
Thus the inhibition by aspirin suggests that COX-2 is a
neuronal NF-κB target gene. To further corroborate this
notion we performed a promoter analysis of the COX-2
gene.
Two conserved κB-binding sites are present in the human 
cyclooxygenase-2 promoter
We noted the presence of two NF-κB consensus motifs
and additional binding sites for Sp-1, AP-2 and NF-IL6
(see Fig. 4A) in the human COX-2 promoter sequence. For
a further analysis of the 5'-upstream region of the COX-2
promoter the sequence from position -495 to +15 was
cloned from human genomic DNA. In order to test if the
cloned sequences have promoter activity, two different
constructs driving a luciferase reporter vector (Clone ABMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/16
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and B in Fig. 4B) were transfected in human embryonic
kidney cells 293, a well established cell line for the analy-
sis of NF-κB activity. As expected both constructs show a
high basal-level promoter activity in comparison to the
promoter-less pGL-2 vector (Fig. 4B).
The cyclooxygenase-2 promoter is strongly induced by NF-
κB activating stimuli
A prerequisite of a NF-κB target gene would be its induci-
bility in cells which respond to known NF-κB activating
stimuli. The phorbol ester phorbol 12-myristate 13-ace-
tate (PMA) is a strong inducer of NF-κB activity [27]. Non-
neuronal cells were used to characterize the mechanisms
of promoter-induction, since neuronal cells support al-
ready a full blown constitutive COX-2 promoter activity
(see below). Therefore we analyzed the COX-2 promoter
for response to activated NF-κB, in comparison to the ex-
clusively NF-κB driven tk(NF-κB)6-luc reporter (Fig. 5).
Both PMA and TNF induced the tk(NF-κB)6-luc reporter
significantly (more than 50-fold for PMA and bout 10-
fold for TNF). A strong increase of luciferase activity in re-
sponse to PMA-stimulation was detected for the COX-2
promoter construct. In contrast, TNFα, a strong activator
of NF-κB did not induce measurable COX-2 promoter ac-
tivity (Fig. 5). The TNF induction of the COX-2 promoter
might not be detectable, since TNF in HeLa cells is a weak-
er activator of NF-κB-dependent reporter genes than PMA
(see induction of the tk(NF-κB)6-luc reporter). These data
also lend crescence to the idea, that TNF is a short time
stimulus which can potently activate NF-κB binding activ-
ity (see Fig. 8) as does PMA. In contrast, the longer lasting
stimulus PMA is also a potent activator of reporter gene
expression due to the short half life of luciferase. PMA also
activates the formation of a transcriptionally active AP-1
complex [28]. But induction of the COX-2 promoter via
AP-1 is very unlikely since there are no binding sites for
AP-1 within the used COX-2 promoter fragment. Another
clue for the involvement of NF-κB in COX-2 gene expres-
sion is derived from cotransfection experiments of the
COX-2 reporter and expression vectors for p65 and p50.
This cotransfection leads to a significant increase of re-
porter gene activity (Fig. 6) demonstrating the strong
transactivational potential of p65 [29]. On the other
hand, cotransfection of p50 shows a similar effect (Fig. 6).
This might be due to the interaction of p50 with Bcl-3 and
is frequently observed also in other promoters [30]. These
data suggest a crucial role of NF-κB as a regulator of COX-
2 promoter activity.
Constitutive NF-κB activity in NB-4 neuroblastoma cells is 
essential for cyclooxygenase-2 promoter activity
We and others have previously shown that many neurons
contain constitutive NF-κB activity both, in primary cul-
tures and in vivo [10,31,24]. For our investigations we
have chosen the murine neuroblastoma cell line NB-4
Figure 1
Co-localization of NF-κB and COX-2 in the cerebral cortex. 
Upper panel showing activated NF-κB (anti-p65 monoclonal 
antibody) in red; middle panel showing COX-2 in green; 
lower panel showing cellular architecture visualized with 
DAPI staining. Note double immunopositive cells (arrow-
heads) with cytoplasmic COX-2 and nuclear NF-κB staining 
(× 400).BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/16
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Figure 2
Co-localization of NF-κB and COX-2 in the hippocampus. a-c) A region of the dentate gyrus is shown. Nuclei of granule cells 
are visualized by DAPI staining (c). a) anti-p65 staining (red), b) anti-COX-2 staining (green); colocalisation of p65 and COX-2 
in some neurons is marked by arrow heads. d-f) A region of the CA3 field is shown. d) anti-p65 staining (red), e) anti-COX-2 
staining (green); colocalisation of p65 and COX-2 in a pyramidal neuron is marked by an arrow head; f) nuclear staining of the 
same blow-up with DAPI. (× 400)BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/16
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Figure 3
NF-κB and COX-2 are repressed by aspirin in cultivated hippocampal slices. Left panel: Control (Con) cultures are treated 
with bicuculline and picrotoxine to influence GABAergic input. Under these conditions NF-κB activity and COX-2 expression 
is similar to the in vivo situation (see Fig. 2). Right panel: cultures were treated with bicuculline and picrotoxine as control cul-
tures and co-treated with aspirin for3 15 min and analyzed 6 h post treatment.3 Note the strong inhibition of nuclear NF-κB 
immunoreactivity and the correlated down regulation of COX-2 expression. (× 400)BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/16
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which displays characteristics of mature cholinergic neu-
rons. In contrast to the non-neuronal cell lines used in the
above described experiments, transfection of a tk(NF-
κB)6-luc reporter revealed a constitutive activation of NF-
κB (Fig. 7A). The activity of the NF-κB-luc reporter in NB-
4 cells was essentially dependent on NF-κB, since it was
totally abrogated after cotransfection of the inhibitory
subunit IκB-α. This constitutive NF-κB activity could also
not be further augmented by stimulation with TNF or
PMA. But a downregulation of NF-κB activity was ob-
served after treatment with PMA and TNF, as described
earlier for PMA-treated HeLa cells [32]. Constitutive NF-
κB activity was described previously also for neurons in
the cortex and the hippocampus [10]. The analysis of the
COX-2 promoter led to a similar result (Fig. 7B), showing
high activity of the promoter without stimulation and dis-
playing a missing responsiveness to the otherwise potent
stimulus PMA. These results provide evidence to the idea
that the constitutive activity of NF-κB found here is al-
ready the full blown activity, which can no longer be af-
fected by activating agents.
The activity of the cyclooxygenase-2 promoter is only de-
pendent on the promoter-distal NF-κB binding-site
For a more detailed analysis of the regulatory involvement
of NF-κB, we tested the two κB-binding sites in the COX-
2 promoter (see Fig. 4A) for their potential to bind NF-κB-
proteins and to stimulate transcription. For the first pur-
pose, electrophoretic mobility shift assays using oligonu-
cleotides corresponding to the two κB-binding sites were
performed (Fig. 8). The promoter-distal NF-κB1-binding
site showed a clear binding activity for nuclear proteins
(Fig. 8, lanes 1–3), whereas the promoter-proximal NF-
κB2-site reproducibly failed in binding (Fig. 8, lanes 4–6).
Figure 4
Analysis of a human COX-2 promoter region. (A) Scheme of the promoter region. Transcription factor binding sites were 
identified using the computer program Factor (HUSAR program package, DKFZ Heidelberg). Note the presence of two NF-κB 
binding sites NF-κB1 (promoter-distal) and NF-κB2 (promoter-proximal). (B) Analysis of COX-2 promoter activity. Two PCR-
generated COX-2 promoter constructs in the promoter-less luciferase vector pGL-2 (Promega, Heidelberg) were choosen for 
transfection in HEK 293 cells. The luciferase activity of the empty vector pGL-2 was set to one. The fold induction of luciferase 
activity is depicted in a linear scale on the ordinate. Both COX-2 promoter constructs show a more than 300-fold activity over 
the promoter-less vector pGL-2. The standard deviation of triplicate transfection assays is depicted as arrow bars.
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The NF-κB binding-site from the κ light chain enhancer
was used as control (Fig. 8, lanes 7–9). These results can
be explained by a nonconsensus nucleotide within the pu-
tative binding site (Fig. 3A). In addition the sequence of
the NF-κB2-site could not be selected as optimal κB/Rel
DNA-binding motif [33]. Therefore the regulation of the
COX-2 promoter via NF-κB is solely dependent on the
promoter-distal NF-κB1-site. To verify this hypothesis, a
mutant of the NF-κB1-site in the COX-2 promoter was
constructed. Mutant and wildtype COX-2 promoter con-
structs were transfected in NB-4 cells and analyzed for lu-
ciferase activity (Fig. 9). In accordance with the EMSA data
mutation of the NF-κB1-site leads to a complete loss of
COX-2 promoter activity. These results underscore the
central role of NF-κB in regulating COX-2 promoter in
neuronal cells: in NB-4 cells the COX-2 promoter is con-
stitutively active and this activation is dependent on the
integrity of the NF-κB1 binding-site in this promoter.
Discussion
Here the regulation of the human COX-2 promoter was
analyzed. Immunocytochemistry was used to colocalize
COX-2 immunoreactivity and activated NF-κB in neurons
in vivo. This was investigated in the rat hippocampus and
cortex cerebri, using an antibody specific for the activated
form of NF-κB. In cultured hippocampal slices the specific
NF-κB inhibitor aspirin, inhibited both, NF-κB activation
and COX-2 expression. The promoter region of the hu-
man COX-2 gene contains, in contrast to the mouse pro-
moter region, two putative NF-κB binding sites. It was
Figure 5
Stimulation of COX-2 promoter activity in HeLa cells. As 
control, a luciferase construct driven by the synthetic NF-κB 
dependent promoter tk(NF-κB)6-luc was transfected in 
HeLa cells. The basal level of the unstimulated promoter was 
set to one. Treatment of transfected cells with 50 ng PMA 
per ml medium for 6 h resulted in a more than 50-fold 
increase in luciferase activity, whereas treatment of trans-
fected cells with TNF α (200 U/ml) resulted in a moderate 
increase (< 10-fold). Within the same assay the COX-2 pro-
moter driven luciferase construct was tested. The activity of 
the promoter without treatment was set to one. PMA 
induced the promoter activity about 30-fold, whereas TNF 
had no measurable effect. Standard deviations of triplicate 
transfection assays are depicted as arrow bars.
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Figure 6
Induction of COX-2 promoter activity by NF-κB subunits. 
Expression vectors for the NF-κB subunits p50 and p65 were 
cotransfected with the COX-2 promoter in HeLa cells. Both 
subunits can activate COX-2 promoter activity. Standard 
deviations of triplicate transfection assays are depicted as 
arrow bars. Fold induction was normalized to control, that is 
the COX-2 promoter reporter vector alone (1 fold induc-
tion).
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Figure 7
Analysis of NF-κB dependent promoter activation in NB-4 
neuroblastoma cells. (A) Analysis of a synthetic NF-κB-
dependent reporter. The synthetic NF-κB-dependent 
reporter-gene tk(NF-κB)6-luc was transfected in NB-4 neu-
roblastoma cells (1). Luciferase activity of tk(NF-κB)6-luc set 
to 100 %. Cotransfection of tk(NF-κB)6-luc with an expres-
sion vector for IκBα totally abrogated the activity of this luci-
ferase reporter (2). Treatment of cells transfected with 
tk(NF-κB)6-luc with PMA (3) or TNFα (5) resulted in a 
reduction of reporter gene activity. This residual activity 
could be further inhibited after expression of IκBα (4). (B) 
Analysis of the human COX-2 promoter. The COX-2-pro-
moter-driven luciferase reporter was transfected in NB-4 
neuroblastoma cells (1). Luciferase activity of COX-2-luc was 
set to 100 %. Cotransfection of COX-2-luc with an expres-
sion vector for IκBα significantly inhibited the activity of this 
luciferase reporter (2). Treatment of cells transfected with 
COX-2-luc with PMA (3) resulted in a slight increase of 
reporter gene activity. This residual activity also could be 
inhibited after expression of IκBα (4). Standard deviations of 
triplicate transfection assays are depicted as arrow bars.
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Figure 8
Electrophoretic mobility shift analysis (EMSA) of NF-κB bind-
ing sites derived from the human COX-2 promoter. Nuclear 
extracts derived form HeLa cells without treatment (-, lanes 
1, 4, 7), with TNFα treatment (lanes 2, 5, 8) and with PMA 
treatment (lanes 3, 6, 9) were used for EMSA with different 
probes. EMSA with a probe spanning the promoter element 
NF-κB1 from the human COX-2 promoter is shown in lane 
1–3. NF-κB2 was used as probe in lane 4–6 and a κB-element 
from the κ light chain enhancer was used as control in lanes 
7–9. The specific NF-κB complex is marked with an arrow-
head.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/16
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found, that only the conserved NF-κB binding site,
present in the mouse and human COX-2 promoter region
(see Fig. 4A), is of functional relevance in neuronal cells.
Evidence for COX-2 as a neuronal NF-κB target gene
Non-neuronal cells were used to characterize the mecha-
nisms of promoter-induction, since neuronal cells sup-
port already a full blown constitutive COX-2 promoter
activity (see below). In HeLa cells the human COX-2 pro-
moter is fully inducible with PMA, but only to a low
amount with TNF, whereas a synthetic NF-κB-dependent
promoter is readily activated with TNF. This difference
might be exaggerated through the lower COX-2 promoter
activity, which is the result of only one functional NF-κB
binding site. During the analysis of NF-κB-subunits medi-
ating an induction of the COX-2 promoter, we found that
the NF-κB subunits p50 and p65 were active. In contrast
to p65, which contains a transactivating domain, the p50
subunit does not contain its own transactivation domain.
This effect might be mediated by interaction of p50 with
Bcl-3, which can provide the transactivating function. This
transactivating effect of the NF-κB p50 subunit is not a
characteristic of the COX-2 promoter but is now frequent-
ly observed also in other promoters [30].
In accordance with the inter-species conservation of the
promoter-distal κB1 element (Fig. 4A), DNA-binding of
NF-κB proteins to this element was detected. The promot-
er proximal κB2 element is different in one nucleotide
from the NF-κB consensus binding site and could not be
bound by NF-κB subunits. In a recent approach recom-
binant NF-κB subunits were used to select target sequenc-
es bound by the DNA-binding domains (target detection
assay). In accordance with our data the κB2 element was
not selected as a binding site [33].
It was reported earlier that many neurons of the cortex cer-
ebri and the hippocampus contain constitutive NF-κB ac-
tivity [10]. Using an antibody specific for activated p65
[24], here a colocalization of constitutive NF-κB activity
and basal level COX-2 expression was detected. In accord-
ance to the constitutive activity detected in vivo we also
found that NB-4 cells contain constitutive activity based
on the following criteria: 1.) A high-level basic activity of
a promoter containing 6 κB elements could not be further
augmented after treatment with PMA or TNF. 2.) Consti-
tutive promoter activity could be repressed with cotrans-
fection of IκB. The COX-2 promoter in NB-4 cells showed
the same level of constitutive activity that could not be
augmented strongly with PMA or TNF, but is repressed af-
ter cotransfection of IκB. Therefore we conclude that NB-
4 neuroblastoma cells are a suitable model for the consti-
tutive NF-κB activity found in vivo in neurons of the cortex
and hippocampus. Here we show that a mutation of the
COX-2 promoter κB1 element entirely abolishes the con-
stitutive activity of this promoter in NB-4 cells.
Recent studies have shown, that NF-κB can be activated in
cerebellar granule cells via stimulation of glutamate recep-
tors [11–13,34]. In addition it was shown that the tran-
scription of NF-κB subunits p50 and p65 was increased
during seizure activity [17]. Taken together NF-κB is one
of the transcription factors regulated via neuronal activity
(see [9]). One of the important physiological consequenc-
es of NF-κB activation might be the induction of a com-
pensatory neuroprotective gene expression program
[14,35–38].
COX-2 mediated inflammatory pathways may play im-
portant roles in pathogenesis of neurodegenrative diseas-
es such as Alzheimer disease [22]. In Alzheimer disease
patients early plaque stages are surrounded by neurons
with activated NF-κB [37,39]. Moreover high levels of NF-
κB binding activity could be strongly correlated to high
levels of COX-2 transcription in Alzheimer disease and
age matched control brains [40]. There is evidence re-
viewed by [41] that induction of high level of COX-2
epression might be responsible for patho-physiological
changes which are also seen in a COX-2 overexpressing
mouse model [42]. But the activation of COX-2 might
Figure 9
Mutational analysis of the COX-2 promoter in NB-4 neurob-
lastoma cells. The activity of a COX-2 promoter construct 
containing both NF-κB binding sites was set to 100 %. A con-
struct containing the same promoter context but a mutation 
of the promoter distal NF-κB1 binding site (κB1mut) had 
only one tenth of wild-type COX-2 promoter activity. These 
data show that the constitutive NF-κB activity of the COX-2 
promoter in NB-4 cells is merely dependent on the func-
tional integrity of the evolutionary conserved NF-κB1 ele-
ment. Standard deviations of triplicate transfection assays are 
depicted as arrow bars.
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also serve protective functions as shown in seizure para-
digms. Seizures can activate NF-κB [43], which in turn
may lead to prostaglandin production after COX-2 gene
induction. These newly produced prostaglandins might
exert a protective effect against new seizure attacks [44].
Non-steroidal anti-inflammatory drugs (NSAIDs) such as
aspirin are the major therapy for inflammatory pain. In
addition to its action as an inhibitor of prostaglandin syn-
thesis aspirin also acts as an inhibitor of NF-κB. A recent
study has shown that inflammatory pain is induced via
COX-2, expressed in neurons within the CNS[25]. Here
we have shown that neuronal COX-2 expression is essen-
tially dependent on NF-κB activity. In addition the NSAID
aspirin inhibits neuronal NF-κB, which results in strongly
reduced COX-2 activity. Similarly an enantiomer of the
NSAID flurbiprofen which could not repress COX-2 en-
zyme activity is still acting anti-phlogistically as an inhib-
itor of NF-κB [45].
Conclusions
We found that COX-2 is a neuronal target gene of NF-κB.
Aspirin inhibited both, NF-κB activation and COX-2 ex-
pression in neurons. Thus preventing COX-2 gene tran-
scription via NF-κB inhibition might provide novel means
of normalizing pain sensitivity.
Methods
Materials
Human genomic DNA was from Promega, Heidelberg,
Germany; Taq-Polymerase and PCR-reagents from Strata-
gene, Heidelberg, Germany. Sequencing was performed
using reagents and equipment from Applied Biosystems
(Weiterstadt, Germany). D-Luciferin, PMA and TNF were
obtained from Sigma, Deisenhofen, Germany; Lipofectin
from Gibco, Karlsruhe, Germany.
Vector construction
The human COX-2 promoter was cloned by PCR using the
following primers: tgcagctcttgactcatcgg and cccaagctt-
gacaattggtcgctaaccga according to a published sequence
[46]. The obtained sequences were cloned in front of the
luciferase gene into the promoter-less luciferases reporter
vector pGL-2 (Promega, Heidelberg, Germany) and ver-
fied by sequencing. For mutational analysis an EcoRI site
was introduced in the κB1 element (κB1mut:gagagaattctc-
cctgcgc) with a PCR-mediated strategy.
Organotypic hippocampal slice cultures
Hippocampal slice cultures (N= 30) were prepared from
slices 350 µm thick taken from five-day-old pubs of Wistar
rats. After 6 days in vitro [47,48] all cultures were treated
with GABA antagonists to mimick the glutamatergic input
present in vivo. All used drugs were from Sigma, Deisen-
hofen, Germany. Treatment with the GABA antagonists
bicuculline (200 µM) and picrotoxine (1000 µM) of all
slice cultures was done as described [49] for 3 days. Cul-
tures were co-treated with aspirin (5 mM for 15 min as de-
scribed [34] and assayed for immunoreactivity after 6 h
post treatment. Cultures were fixed with 4% formaldehyd
(pH 7.2) for 12–24 h at room temperature, kryoprotected
in 30% sucrose solution (overnight at 4°C) and sectioned
with a kryostat (20 µm).
Immunocytochemistry was done as detailed below.
Culture of cell lines
Cell lines were obtained from the American Type Culture
Collection (Rockville, MD, USA). HeLa and 293 cells were
grown in DMEM (Gibco) containing 10% fetal calf serum.
NB-4 cells were cultivated in Ham's F10 medium (Sigma,
Deisenhofen, Germany) with addition of 15% horse se-
rum, 2.5% fetal calf serum, antibiotics and glutamine. For
luciferase assays, cells were plated in six-well plates
(25.000 cells per well with 2 ml of culture medium).
Transfection of cells and luciferase reporter assays
The Rc/CMV derived expression vectors for p50 and p65
were described earlier [29]. The tk(NF-κB)6 luciferase re-
porter construct contains 6 reiterated copies of the HIV-1
κB-site in front of the truncated Herpes simplex thymi-
dine kinase (tk) promoter spanning position -105 to +51
[50]. HeLa and 293 cells were transfected according to a
modified calcium phosphate protocol [51]. NB-4 cultures
were transfected using lipofectin according to the instruc-
tions of the manufacturer (Gibco, Karlsruhe, Germany).
Twenty hours after transfection, cells were lysed and as-
sayed for luciferase activity [52]. At least three independ-
ent transfection experiments were performed in triplicates
using different cell and DNA preparations. All experi-
ments gave the same qualitative result. One representative
experiment is shown. In several experiments cells were
stimulated for 6 h with either 50 ng/ml PMA (Sigma, De-
isenhofen, Germany) or 2 ng/ml (200 U/ml) human TNF-
α (Roche, Mannheim, Germany).
Electrophoretic mobility shift assay (EMSA)
Nuclear proteins were prepared as previously described
[32]. Briefly, cells were lysed in buffer A containing 20
mM HEPES, 0.35 M NaCl, 20% glycerol, 1% Nonidet P-
40, 1 mM MgCl2, 0.5 M EDTA, 0.1 mM EGTA, 5 mM
dithiothreitol, phenylmethylsulfonyl fluoride and apro-
tinin. Nuclei were extracted with buffer C and stored at -
80°C for EMSA. EMSAs were performed using 3.5 µg nu-
clear proteins to bind to 32P-labeled oligonucleotides, en-
compassing the κB-site from the murine κ light chain
enhancer (Promega, Heidelberg, Germany), κB1: gagag-
gggattccctgcg and κB2:agtgggactaccccctc from the human
COX-2 promoter.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/16
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Immunocytochemistry
Brains were dissected from adult Wistar rats and embed-
ded in OTC-compound (Miles-Bayer, Leverkusen, Germa-
ny). 8 µm cryo-sections were cut from snap frozen
material with a Leica cryostat (Leica Instruments, Heidel-
berg, Germany). The sections were collected on gelatine
coated slides and dried. After fixation in methanol at -
20°C for 5 min, the sections were blocked in 5% goat se-
rum. For double-label immunofluorescence the sections
were incubated with the two primary antibodies (diluted
1:50): a monoclonal antibody against p65 (Roche, Ger-
many, see [24] and a rabbit polyclonal antibody against
murine COX-2 (cyclooxygenase-2, Cayman Chemical
Company, Ann Arbor, USA). Bound antibodies were de-
tected with an anti-mouse IgG antibody coupled with Cy3
(1:1000, Dianova, Hamburg, Germany) and an anti-rab-
bit IgG coupled with DTAF (1:100, Dianova, Hamburg).
Nuclei were stained with DAPI (4',6-Diamidine-2'phe-
nylindole dihydrochloride, Roche, Germany). Micro-
photographs were taken with a Zeiss Axioskop equipped
with epifluorescence. Mounting of colour plates was done
on an Apple PowerPC with Adobe Photoshop.
List of abbreviations
AP, activator protein; C/EBP, CCAAT/enhancer binding
protein; COX-2, cyclooxygenase-2; DAPI, 4',6-Diamidine-
2'phenylindole dihydrochloride; EMSA, electrophoretic
mobility shift assay; IκB-α, Inhibitor of kappaB-alpha;
IKK, IkappaB kinase; NEMO, NF-kappaB Essential MOdu-
lator; NF-κB, nuclear factor kappa B; PMA, phorbol ester;
TNF-α, tumor necrosis factor alpha.
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